Characteristics and therapeutic results of retrospective and prospective studies of R/R PVRL
| Reference . | Type of study . | n . | Median age (range), y . | Systemic treatment . | Response . | CNS relapse . | Survival . |
|---|---|---|---|---|---|---|---|
| 92 | Prospective phase 1 trial | 5* | 66 (47-79) | Lenalidomide (10-30 mg/d for 21 d of 28-d cycle) ± rituximab IV + intraventricular | CR: n = 1 PR: n = 3 SD: n = 1 | NA | PFS: 1.75, 6, 9, 21, and 48+ mo |
| 89 | Prospective multicenter phase 2 trial | 17† | 69 (46-86) | Rituximab IV (375 mg/m2) lenalidomide (20-25 mg/d for 21 d of 28-d cycle) | CR = 35% | NA Median follow- up = 19 mo | Median PFS = 9.2 mo Median OS not reached |
| 90 | Prospective multicenter phase II trial | 14† | 67 (47-82) | Ibrutinib (560 mg/d) | CR = 50% | N = 1 Median follow- up = 26 mo | Median PFS = 23 mo |
| 88 | Retrospective multicenter study | 21 | 75 (35-90) | Temozolomide (150 mg/m2/d × 5) | CR = 71% | N = 5 Median follow- up = 42 mo | PFS = 12 mo |
| 101 | Retrospective study | 10 | NA | Ifosfamide IV or trofosfamide orally | CR: n = 9 PR: n = 1 | N = 2 | PFS = 18 mo OS = 32 mo |
| 83 ‡ | Retrospective study | 5 | NA | TBC + ASCT | CR: n = 5 | N = 0 | 3 patients alive at 14, 14, and 15 mo |
| 84 ‡ | Retrospective study | 11* | 53 (27-64) | TBC + ASCT | CR: n = 9 PR: n = 2 | N = 0 Median follow- up = 41.5 mo | 7 patients alive in CR at 18, 28, 41, 45, 49, 62, 69, and 70 mo |
| 85 | Retrospective study | 11* | 52 (23-67) | TBC + ASCT | NA for the PVRL subgroup of patients | 5-y PFS = 50% (no significant difference between patients with PVRL and PCNSL) | |
| Reference . | Type of study . | n . | Median age (range), y . | Systemic treatment . | Response . | CNS relapse . | Survival . |
|---|---|---|---|---|---|---|---|
| 92 | Prospective phase 1 trial | 5* | 66 (47-79) | Lenalidomide (10-30 mg/d for 21 d of 28-d cycle) ± rituximab IV + intraventricular | CR: n = 1 PR: n = 3 SD: n = 1 | NA | PFS: 1.75, 6, 9, 21, and 48+ mo |
| 89 | Prospective multicenter phase 2 trial | 17† | 69 (46-86) | Rituximab IV (375 mg/m2) lenalidomide (20-25 mg/d for 21 d of 28-d cycle) | CR = 35% | NA Median follow- up = 19 mo | Median PFS = 9.2 mo Median OS not reached |
| 90 | Prospective multicenter phase II trial | 14† | 67 (47-82) | Ibrutinib (560 mg/d) | CR = 50% | N = 1 Median follow- up = 26 mo | Median PFS = 23 mo |
| 88 | Retrospective multicenter study | 21 | 75 (35-90) | Temozolomide (150 mg/m2/d × 5) | CR = 71% | N = 5 Median follow- up = 42 mo | PFS = 12 mo |
| 101 | Retrospective study | 10 | NA | Ifosfamide IV or trofosfamide orally | CR: n = 9 PR: n = 1 | N = 2 | PFS = 18 mo OS = 32 mo |
| 83 ‡ | Retrospective study | 5 | NA | TBC + ASCT | CR: n = 5 | N = 0 | 3 patients alive at 14, 14, and 15 mo |
| 84 ‡ | Retrospective study | 11* | 53 (27-64) | TBC + ASCT | CR: n = 9 PR: n = 2 | N = 0 Median follow- up = 41.5 mo | 7 patients alive in CR at 18, 28, 41, 45, 49, 62, 69, and 70 mo |
| 85 | Retrospective study | 11* | 52 (23-67) | TBC + ASCT | NA for the PVRL subgroup of patients | 5-y PFS = 50% (no significant difference between patients with PVRL and PCNSL) | |
NA, not available; PR, partial response; TBC, thiotepa (750 mg/m2), busulfan (8 mg/kg), and cyclophosphamide (120 mg/kg).
N of patients with intraocular lymphoma (isolated intraocular relapse of primary CNS lymphoma, n = 3; intraocular and brain relapse of systemic lymphoma, n = 1; intraocular and brain relapse of primary CNS lymphoma, n = 1).
N of patients included in the studies with isolated intraocular disease involvement (R/R PVRL and intraocular relapse of PCNSL).
These 2 studies did not include the same patients.